📣 VC round data is live. Check it out!
- Public Comps
- Castle Biosciences
Castle Biosciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for Castle Biosciences and similar public comparables like Lumibird, Assure Tech, Integral Diagnostics, Jiangsu Bioperfectus and more.
Castle Biosciences Overview
About Castle Biosciences
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
Founded
2007
HQ

Employees
761
Website
Financials (LTM)
EV
$399M
Valuation Multiples
Start free trialCastle Biosciences Financials
Castle Biosciences reported last 12-month revenue of $347M and EBITDA of $28M.
In the same LTM period, Castle Biosciences generated $264M in gross profit, $28M in EBITDA, and had net loss of ($32M).
Revenue (LTM)
Castle Biosciences P&L
In the most recent fiscal year, Castle Biosciences reported revenue of $344M and EBITDA of $43M.
Castle Biosciences is unprofitable as of last fiscal year, with gross margin of 79%, EBITDA margin of 13%, and net margin of (7%).
Financial data powered by Morningstar, Inc.
Castle Biosciences Stock Performance
Castle Biosciences has current market cap of $624M, and enterprise value of $399M.
Market Cap Evolution
Castle Biosciences' stock price is $20.56.
Castle Biosciences share price decreased by 16.0% in the last 30 days, and increased by 28.7% in the last year.
Castle Biosciences has an EPS (earnings per share) of $-0.80.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $399M | $624M | 2.6% | -16.0% | -30.5% | 28.7% | $-0.80 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCastle Biosciences Valuation Multiples
Castle Biosciences trades at 1.1x EV/Revenue multiple, and 14.4x EV/EBITDA.
EV / Revenue (LTM)
Castle Biosciences Financial Valuation Multiples
As of May 22, 2026, Castle Biosciences has market cap of $624M and EV of $399M.
Castle Biosciences has a P/E ratio of (19.5x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Castle Biosciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Castle Biosciences Margins & Growth Rates
Castle Biosciences grew revenue by 2% but EBITDA decreased by 92% in the last fiscal year.
In the most recent fiscal year, Castle Biosciences reported gross margin of 79%, EBITDA margin of 13%, and net margin of (7%).
Castle Biosciences Margins
Castle Biosciences Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Castle Biosciences Operational KPIs
Castle Biosciences' revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.4M for the same period.
Castle Biosciences' Rule of 40 is 3% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Castle Biosciences' Rule of X is 7% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Castle Biosciences Competitors
Castle Biosciences competitors include Lumibird, Assure Tech, Integral Diagnostics, Jiangsu Bioperfectus, RaySearch Labs, Abclon, Genfit, Fulgent Genetics, Diagnósticos da América and Mirxes Holding.
Most Castle Biosciences public comparables operate across Diagnostics & Genomics, Medical Imaging & Diagnostics, BioTech, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 2.7x | 2.6x | 13.6x | 12.7x | |||
| 6.2x | — | 22.7x | — | |||
| 2.1x | 1.7x | 12.1x | 8.3x | |||
| 10.9x | — | 112.2x | — | |||
| 4.8x | 4.8x | 11.1x | 10.8x | |||
| 153.5x | — | (44.3x) | — | |||
| 6.8x | 6.7x | (15.9x) | (27.7x) | |||
| 0.7x | 0.7x | (22.7x) | (8.3x) | |||
This data is available for Pro users. Sign up to see all Castle Biosciences competitors and their valuation data. Start Free Trial | ||||||
Castle Biosciences Funding History
Before going public, Castle Biosciences raised $44M in total equity funding, across 6 rounds.
Castle Biosciences Funding Rounds
Castle Biosciences M&A Activity
Castle Biosciences has acquired 4 companies to date.
Last acquisition by Castle Biosciences was on May 5th 2025. Castle Biosciences acquired Previse for undisclosed valuation.
Latest Acquisitions by Castle Biosciences
| Description | Previse is a Baltimore-headquartered biotechnology firm founded in 2020, concentrating on diagnostics, medical devices, therapeutics, and MedTech for early disease detection. The company develops AI-enhanced platforms for precision medicine, targeting cardiovascular and oncology applications with clinical validation studies underway in U.S. hospitals. | AltheaDx is a molecular diagnostics company offering PCR-based assays and biomarker services for oncology and infectious diseases. Its lab processes samples for gene expression, genotyping, and NGS panels supporting clinical trials. Located in San Diego, AltheaDx provides CLIA-certified testing for pharmaceutical partners evaluating companion diagnostics. | Cernostics is a life sciences company developing molecular diagnostic tests for cancer using its TissueCypher platform. Pittsburgh-headquartered, the technology analyzes whole-slide images with multiplexed immunofluorescence to assess tumor microenvironments in esophageal and gastric cancers. Cernostics partners with pharma companies for companion diagnostics supporting immunotherapy decisions. | MyPath Melanoma is a Salt Lake City-based CLIA-certified laboratory service from Castle Biosciences offering gene expression profiling for indeterminate melanocytic lesions. The assay distinguishes invasive melanoma from nevi using 23-gene signature, aiding dermatopathologists in risk stratification. Deployed since 2017, it supports treatment decisions in early-stage diagnostics. |
| HQ Country | ||||
| HQ City | Baltimore, MD | San Diego, CA | San Francisco, CA | Salt Lake City, UT |
| Deal Date | 5 May 2025 | 4 Apr 2022 | 19 Oct 2021 | 27 Apr 2021 |
| Valuation | undisclosed | $65M | $3B | $33M |
| EV/Revenue | ||||
| EV/EBITDA | ||||
This data is available for Pro users. Sign up to see all Castle Biosciences acquisitions and their M&A valuation multiples. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Castle Biosciences
| When was Castle Biosciences founded? | Castle Biosciences was founded in 2007. |
| Where is Castle Biosciences headquartered? | Castle Biosciences is headquartered in United States. |
| How many employees does Castle Biosciences have? | As of today, Castle Biosciences has over 761 employees. |
| Who is the CEO of Castle Biosciences? | Castle Biosciences' CEO is Derek J. Maetzold. |
| Is Castle Biosciences publicly listed? | Yes, Castle Biosciences is a public company listed on Nasdaq. |
| What is the stock symbol of Castle Biosciences? | Castle Biosciences trades under CSTL ticker. |
| When did Castle Biosciences go public? | Castle Biosciences went public in 2019. |
| Who are competitors of Castle Biosciences? | Castle Biosciences main competitors include Lumibird, Assure Tech, Integral Diagnostics, Jiangsu Bioperfectus, RaySearch Labs, Abclon, Genfit, Fulgent Genetics, Diagnósticos da América, Mirxes Holding. |
| What is the current market cap of Castle Biosciences? | Castle Biosciences' current market cap is $624M. |
| What is the current revenue of Castle Biosciences? | Castle Biosciences' last 12 months revenue is $347M. |
| What is the current revenue growth of Castle Biosciences? | Castle Biosciences revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Castle Biosciences? | Current revenue multiple of Castle Biosciences is 1.1x. |
| Is Castle Biosciences profitable? | Yes, Castle Biosciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Castle Biosciences? | Castle Biosciences' last 12 months EBITDA is $28M. |
| What is Castle Biosciences' EBITDA margin? | Castle Biosciences' last 12 months EBITDA margin is 8%. |
| What is the current EV/EBITDA multiple of Castle Biosciences? | Current EBITDA multiple of Castle Biosciences is 14.4x. |
| What is the current FCF of Castle Biosciences? | Castle Biosciences' last 12 months FCF is $6M. |
| What is Castle Biosciences' FCF margin? | Castle Biosciences' last 12 months FCF margin is 2%. |
| What is the current EV/FCF multiple of Castle Biosciences? | Current FCF multiple of Castle Biosciences is 61.9x. |
| How many companies Castle Biosciences has acquired to date? | As of May 2026, Castle Biosciences has acquired 4 companies. |
| What was the largest acquisition by Castle Biosciences? | $3B acquisition of Cernostics on 19th October 2021 was the largest M&A Castle Biosciences has done to date. |
| What companies Castle Biosciences acquired? | Castle Biosciences acquired Cernostics, AltheaDx, MyPath Melanoma, and Previse. |
| In how many companies Castle Biosciences has invested to date? | Castle Biosciences hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Castle Biosciences
Lists including Castle Biosciences
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
